Global Antivenom Market: By Antivenom Type (Monovalent, Bivalent, Trivalent, Tetravalent, and Polyvalent), By Reptile Type (Snakes, Scorpions, Spiders, and Others), By Immunoglobulin Type (Homologous and Heterologous), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Others), and Geography (North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa) - Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023
Global Antivenom Market Report Description:
Global antivenom market report gives comprehensive outlook on antivenom products across the globe with special emphasis on key regions such as North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa (MEA). The report on antivenom market gives historical, current, and future market sizes (US$ Mn) on the basis of antivenom type, reptile type, immunoglobulin type, distribution channel, and geographic regions. This report studies antivenom market dynamics elaborately to identify the current market trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, antivenom market report includes the competition analysis with vividly illustrated the competition dashboard to assess the market competition. Moreover, PBI analyzed antivenom market to better equip clients with possible investment opportunities across the regions (Regional Investment Hot-Spots) and market unmet needs. Key stakeholders of the antivenom market report include raw material suppliers, manufacturers, marketers, hospitals, physician offices, policy makers, and healthcare service providers who are engaged in usage and advocacy of antivenom products.
Global Antivenom Market:
Global antivenom market was valued around US$ 1,100 Mn in 2016 and poised to grow around 6.0% CAGR over 2017-2023.
COMPETITION ASSESSMENT
Key players profiles in the global antivenom market include:
By Antivenom Type
Global antivenom market report gives comprehensive outlook on antivenom products across the globe with special emphasis on key regions such as North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa (MEA). The report on antivenom market gives historical, current, and future market sizes (US$ Mn) on the basis of antivenom type, reptile type, immunoglobulin type, distribution channel, and geographic regions. This report studies antivenom market dynamics elaborately to identify the current market trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, antivenom market report includes the competition analysis with vividly illustrated the competition dashboard to assess the market competition. Moreover, PBI analyzed antivenom market to better equip clients with possible investment opportunities across the regions (Regional Investment Hot-Spots) and market unmet needs. Key stakeholders of the antivenom market report include raw material suppliers, manufacturers, marketers, hospitals, physician offices, policy makers, and healthcare service providers who are engaged in usage and advocacy of antivenom products.
Global Antivenom Market:
Global antivenom market was valued around US$ 1,100 Mn in 2016 and poised to grow around 6.0% CAGR over 2017-2023.
COMPETITION ASSESSMENT
Key players profiles in the global antivenom market include:
- Vins Bioproducts Limited (India)
- Bharat Serum and Vaccines Limited (India)
- CSL Limited (Victoria)
- Rare Disease Therapeutics, Inc. (U.S.)
- F. Hoffmann-La Roche AG (Switzerland)
- Instituto Bioclon, S.A. de C.V.(Mexico)
- Incepta Vaccine Ltd. (Bangladesh)
- BTG Plc (UK)
- Merck & Co., Inc. (U.S)
- Pfizer Inc. (U.S.)
- The report provides granular level information about the market size, regional market share, historic market (2012-2016) and forecast (2017-2023)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
- The Report Outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments and startup’s details that are actively working in the market
- The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
- The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market
By Antivenom Type
- Monovalent
- Bivalent
- Trivalent
- Tetravalent
- Polyvalent
- Snakes
- Scorpions
- Spiders
- Others
- Homologous
- Heterologous
- Hospital Pharmacies
- Retail Pharmacies
- Others
- North America
- U.S
- Canada
- Europe
- Germany
- France
- U.K
- Italy
- Spain
- Russia
- Poland
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Australia & New Zealand
- ASEAN (Includes Indonesia, Thailand, Vietnam, Philippines, Malaysia, and Others)
- South Korea
- Rest of Asia-Pacific
- Latin America
- Brazil
- Mexico
- Argentina
- Venezuela
- Rest of Latin America
- Middle East and Africa (MEA)
- Gulf Cooperation Council (GCC) Countries
- Israel
- South Africa
- Rest of MEA
1. EXECUTIVE SUMMARY
2. GLOBAL ANTIVENOM MARKET INTRODUCTION
2.1. Global Antivenom Market – Taxonomy
2.2. Global Antivenom Market–Definitions
2.2.1. Antivenom Type
2.2.2. Reptile Type
2.2.3. Immunoglobulin Type
2.2.4. Distribution Channel
2.2.5. Region
3. GLOBAL ANTIVENOM MARKET DYNAMICS
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Antivenom Market Dynamics – Factors Impact Analysis
3.6. Global Antivenom Market Dynamics – Regulations
3.6.1. U.S
3.6.2. Europe
3.6.3. Japan
3.6.4. China
3.7. Global Antivenom Market– Product Innovations
3.9. Price Analysis
3.10. Technological Landscape
3.11. Value Chain Analysis
3.12. Competitor Landscape
3.13. Recent Flexible e-paper Product Launches
3.14. Funds raised by the Start-ups
3.15. Collaborations and acquisitions in market
4. GLOBAL ANTIVENOM MARKET ANALYSIS 2017 – 2025
4.1. Market Analysis and Forecast, 2017 – 2025 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Opportunity Analysis
5. GLOBAL ANTIVENOM MARKET, BY ANTIVENOM TYPE, 2017 - 2023
5.1. Monovalent
5.1.1. Market Analysis and Forecast, 2017 – 2025 (Revenue, USD Mn)
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
5.1.3. Market Opportunity Analysis
5.2. Bivalent
5.2.1. Market Analysis and Forecast, 2017 – 2025 (Revenue, USD Mn)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
5.2.3. Market Opportunity Analysis
5.3. Trivalent
5.3.1. Market Analysis and Forecast, 2017 – 2025 (Revenue, USD Mn)
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
5.3.3. Market Opportunity Analysis
5.4. Tetravalent
5.4.1. Market Analysis and Forecast, 2017 – 2025 (Revenue, USD Mn)
5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
5.4.3. Market Opportunity Analysis
5.5. Polyvalent
5.5.1. Market Analysis and Forecast, 2017 – 2025 (Revenue, USD Mn)
5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
5.5.3. Market Opportunity Analysis
6. GLOBAL ANTIVENOM MARKET, BY REPTILE TYPE, 2017 - 2023
6.1. Snakes
6.1.1. Market Analysis and Forecast, 2017 – 2025 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
6.2.3. Market Opportunity Analysis
6.2. Scorpions
6.2.1. Market Analysis and Forecast, 2017 – 2025 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
6.2.3. Market Opportunity Analysis
6.3. Others
6.3.1. Market Analysis and Forecast, 2017 – 2025 (Revenue, USD Mn)
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
6.2.3. Market Opportunity Analysis
7. GLOBAL ANTIVENOM MARKET FORECAST, BY IMMUNOGLOBULIN TYPE, 2017 - 2023
7.1. Homologous
7.1.1. Market Analysis and Forecast, 2017 – 2025 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
7.1.3. Market Opportunity Analysis
7.2. Heterologus
7.2.1. Market Analysis and Forecast, 2017 – 2025 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
7.2.3. Market Opportunity Analysis
8. GLOBAL ANTIVENOM MARKET FORECAST, BY DISTRIBUTION CHANNEL, 2017 - 2023
8.1. Hospital Pharmacies
8.1.1. Market Analysis and Forecast, 2017 – 2025 (Revenue, USD Mn)
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
8.1.3. Market Opportunity Analysis
8.2. Retail Pharmacies
8.2.1. Market Analysis and Forecast, 2017 – 2025 (Revenue, USD Mn)
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
8.2.3. Market Opportunity Analysis
9. GLOBAL ANTIVENOM MARKET FORECAST, BY REGION, 2017 - 2023
9.1. North America
9.1.1. Market Analysis and Forecast, 2017 – 2025 (Revenue, USD Mn)
9.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
9.1.3. Market Opportunity Analysis
9.2. Europe
9.2.1. Market Analysis and Forecast, 2017 – 2025 (Revenue, USD Mn)
9.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
9.2.3. Market Opportunity Analysis
9.3. Asia-Pacific
9.3.1. Market Analysis and Forecast, 2017 – 2025 (Revenue, USD Mn)
9.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
9.3.3. Market Opportunity Analysis
9.4. Latin America
9.4.1. Market Analysis and Forecast, 2017 – 2025 (Revenue, USD Mn)
9.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
9.4.3. Market Opportunity Analysis
9.5. Middle East & Africa
9.5.1. Market Analysis and Forecast, 2017 – 2025 (Revenue, USD Mn)
9.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
9.5.3. Market Opportunity Analysis
9.6. Global Antivenom Market - Opportunity Analysis Index, By Antivenom Type, Reptile Type, Immunoglobulin Type, Distribution Channel and Region, 2017 – 2025
10. NORTH AMERICA ANTIVENOM MARKET ANALYSIS 2017 - 2023
10.1.1. Antivenom Type Analysis Forecast (2017 – 2025) by Revenue (USD Mn), Y-o-Y
Growth (%), and Market Share (%)
10.1.1.1. Monovalent
10.1.1.2. Bivalent
10.1.1.3. Trivalent
10.1.1.4. Tetravalent
10.1.1.5. Polyvalent
10.1.2. Reptile Type Analysis Forecast (2017 – 2025) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.1.2.1. Snakes
10.1.2.2. Scorpions
10.1.2.3. Others
10.1.3. Immunoglobulin Type Analysis Forecast (2017 – 2025) by Revenue (USD Mn), Y-o-Y
Growth (%), and Market Share (%)
10.1.3.1. Homologous
10.1.3.2. Heterologous
10.1.4.Distribution Channel Analysis Forecast (2017 – 2025) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.1.4.1. Hospital Pharmacies
10.1.4.2. Retail Pharmacies
10.1.4.5. Others
10.1.5. Country Analysis Forecast (2017 – 2025) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.1.5.1. U.S
10.1.5.2. Canada
10.1.6. North America Antivenom Market - Opportunity Analysis Index, By Antivenom Type, Reptile Type, Immunoglobulin Type, Distribution Channel, and Country, 2017 – 2025
10.1.7. North America Antivenom Market Dynamics - Trends
11. EUROPE ANTIVENOM MARKET ANALYSIS 2017 - 2023
11.1.1.Antivenom Type Analysis Forecast (2017 – 2025) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.1.1. Monovalent
11.1.1.2. Bivalent
11.1.1.3. Trivalent
11.1.1.4. Tetravalent
11.1.1.5. Polyvalent
11.1.2.Reptile Type Analysis Forecast (2017 – 2025) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.2 Snakes
11.1.2.1. Scorpions
11.1.2.2. Others
11.1.3.Immunoglobulin Type Analysis Forecast (2017 – 2025) by Revenue (USD Mn), -o-Y Growth (%), and Market Share (%)
11.1.3.1. Homologous
11.1.3.2. Heterologus
11.1.4.Distribution Channel Analysis Forecast (2017 – 2025) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.4.1. Hospital Pharmacies
11.1.4.2. Retail Pharmacies
11.1.4.5. Others
11.1.5. Country Analysis Forecast (2017 – 2025) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.5.1. Germany
11.1.5.2. UK
11.1.5.3. France
11.1.5.4. Italy
11.1.5.5. Spain
11.1.5.6. Poland
11.1.5.7. Russia
11.1.5.8. Rest of Europe
11.1.6. Europe Antivenom Market - Opportunity Analysis Index, By Antivenom Type, Reptile Type, Immunoglobulin Type, Distribution Channel, and Country, 2017 – 2025
11.1.7. Europe Antivenom Market Dynamics - Trends
12. ASIA-PACIFIC ANTIVENOM MARKET ANALYSIS 2017 - 2023
12.1.1.Antivenom Type Analysis Forecast (2017 – 2025) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.1.1. Monovalent
12.1.1.2. Bivalent
12.1.1.3. Trivalent
12.1.1.4. Tetravalent
12.1.1.5. Polyvalent
12.1.2. Reptile Type Analysis Forecast (2017 – 2025) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.2.1. Snakes
12.1.2.2. Scorpions
12.1.2.3. Others
12.1.3. Immunoglobulin Type Analysis Forecast (2017 – 2025) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.3.1. Homologous
12.1.3.2. Heterologous
12.1.4. Distribution Channel Analysis Forecast (2017 – 2025) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.4.1. Hospital Pharmacies
12.1.4.2. Retail Pharmacies
12.1.4.5. Others
12.1.5. Country Analysis Forecast (2017 – 2025) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.5.1. Japan
12.1.5.2. China
12.1.5.3. India
12.1.5.4. ASEAN
12.1.5.5. Australia & New Zealand
12.1.5.6. Rest of APAC
12.1.6. Asia-Pacific Antivenom Market - Opportunity Analysis Index, By Antivenom Type, Reptile Type, Immunoglobulin Type, Distribution Channel, and Country, 2017 – 2025
12.1.7. Asia-Pacific Antivenom Market Dynamics - Trends
13. LATIN AMERICA ANTIVENOM MARKET ANALYSIS 2017 - 2023
13.1.1. Antivenom Type Analysis Forecast (2017 – 2025) by Revenue (USD Mn), Y-o-Y
Growth (%), and Market Share (%)
13.1.1.1. Monovalent
13.1.1.2. Bivalent
13.1.1.3. Trivalent
13.1.1.4. Tetravalent
13.1.1.5. Polyvalent
13.1.2. Reptile Type Analysis Forecast (2017 – 2025) by Revenue (USD Mn), Y-o-Y
Growth (%), and Market Share (%)
13.1.2.1. Snakes
13.1.2.2. Scorpions
13.1.2.3. Others
13.1.3. Immunoglobulin Type Analysis Forecast (2017 – 2025) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.1.3.1. Homologous
13.1.3.2. Heterologous
13.1.4. Distribution Channel Analysis Forecast (2017 – 2025) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.1.4.1. Hospital Pharmacies
13.1.4.2. Retail Pharmacies
13.1.4.5. Others
13.1.5. Country Analysis Forecast (2017 – 2025) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.1.5.1. Brazil
13.1.5.2. Mexico
13.1.5.3. Argentina
13.1.5.4. Venezuela
13.1.5.5. Rest of Latin America
13.1.6. Latin America Antivenom Market - Opportunity Analysis Index, By Antivenom Type, Reptile Type, Immunoglobulin Type, Distribution Channel, and Country, 2017 – 2025
13.1.7. Latin America Antivenom Market Dynamics - Trends
14. MIDDLE EAST & AFRICA ANTIVENOM MARKET ANALYSIS 2017 - 2023
14.1.1.Antivenom Type Analysis Forecast (2017 – 2025) by Revenue (USD Mn), Y-o-Y
Growth (%), and Market Share (%)
14.1.1.1. Monovalent
14.1.1.2. Bivalent
14.1.1.3. Trivalent
14.1.1.4. Tetravalent
14.1.1.5. Polyvalent
14.1.1.6.
14.1.1.7.
14.1.1.9.
14.1.2.Reptile Type Analysis Forecast (2017 – 2025) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
14.1.2.1. Snakes
14.1.2.2. Scorpions
14.1.2.3. Others
14.1.3.Immunoglobulin Type Analysis Forecast (2017 – 2025) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
14.1.3.1. Homologous
14.1.3.2. Heterologous
14.1.4.Distribution Channel Analysis Forecast (2017 – 2025) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
14.1.4.1. Hospital Pharmacies
14.1.4.2. Retail Pharmacies
14.1.4.5. Others
14.1.5. Country Analysis Forecast (2017 – 2025) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
14.1.5.1. Gulf Cooperation Council (GCC) Countries
14.1.5.2. Israel
14.1.5.3. South Africa
14.1.5.4. Rest of MEA
14.1.6. Middle East & Africa Antivenom Market - Opportunity Analysis Index, By Antivenom
Type, Reptile Type, Immunoglobulin Type, Distribution Channel, and Country, 2017 – 2025
14.1.7. Middle East & Africa Dynamics - Trends
15. COMPETITION LANDSCAPE
15.1. Strategic Dashboard of Top Market Players
15.2. Company Profiles (Introduction, Financial Analysis Product & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
15.2.1. Vins Bioproducts Limited (India)
15.2.2. Bharat Serum and Vaccines Limited (India)
15.2.3. CSL Limited (Victoria)
15.2.4. Rare Disease Therapeutics, Inc. (U.S.)
15.2.5. F. Hoffmann-La Roche AG (Switzerland)
15.2.6. Instituto Bioclon, S.A. de C.V.(Mexico)
15.2.7. Incepta Vaccine Ltd. (Bangladesh)
15.2.8. BTG Plc (UK)
15.2.9. Merck & Co., Inc. (U.S)
15.2.10. Pfizer Inc. (U.S.)
16. RESEARCH METHODOLOGY
17. KEY ASSUMPTIONS AND ACRONY
2. GLOBAL ANTIVENOM MARKET INTRODUCTION
2.1. Global Antivenom Market – Taxonomy
2.2. Global Antivenom Market–Definitions
2.2.1. Antivenom Type
2.2.2. Reptile Type
2.2.3. Immunoglobulin Type
2.2.4. Distribution Channel
2.2.5. Region
3. GLOBAL ANTIVENOM MARKET DYNAMICS
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Antivenom Market Dynamics – Factors Impact Analysis
3.6. Global Antivenom Market Dynamics – Regulations
3.6.1. U.S
3.6.2. Europe
3.6.3. Japan
3.6.4. China
3.7. Global Antivenom Market– Product Innovations
3.9. Price Analysis
3.10. Technological Landscape
3.11. Value Chain Analysis
3.12. Competitor Landscape
3.13. Recent Flexible e-paper Product Launches
3.14. Funds raised by the Start-ups
3.15. Collaborations and acquisitions in market
4. GLOBAL ANTIVENOM MARKET ANALYSIS 2017 – 2025
4.1. Market Analysis and Forecast, 2017 – 2025 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Opportunity Analysis
5. GLOBAL ANTIVENOM MARKET, BY ANTIVENOM TYPE, 2017 - 2023
5.1. Monovalent
5.1.1. Market Analysis and Forecast, 2017 – 2025 (Revenue, USD Mn)
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
5.1.3. Market Opportunity Analysis
5.2. Bivalent
5.2.1. Market Analysis and Forecast, 2017 – 2025 (Revenue, USD Mn)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
5.2.3. Market Opportunity Analysis
5.3. Trivalent
5.3.1. Market Analysis and Forecast, 2017 – 2025 (Revenue, USD Mn)
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
5.3.3. Market Opportunity Analysis
5.4. Tetravalent
5.4.1. Market Analysis and Forecast, 2017 – 2025 (Revenue, USD Mn)
5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
5.4.3. Market Opportunity Analysis
5.5. Polyvalent
5.5.1. Market Analysis and Forecast, 2017 – 2025 (Revenue, USD Mn)
5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
5.5.3. Market Opportunity Analysis
6. GLOBAL ANTIVENOM MARKET, BY REPTILE TYPE, 2017 - 2023
6.1. Snakes
6.1.1. Market Analysis and Forecast, 2017 – 2025 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
6.2.3. Market Opportunity Analysis
6.2. Scorpions
6.2.1. Market Analysis and Forecast, 2017 – 2025 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
6.2.3. Market Opportunity Analysis
6.3. Others
6.3.1. Market Analysis and Forecast, 2017 – 2025 (Revenue, USD Mn)
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
6.2.3. Market Opportunity Analysis
7. GLOBAL ANTIVENOM MARKET FORECAST, BY IMMUNOGLOBULIN TYPE, 2017 - 2023
7.1. Homologous
7.1.1. Market Analysis and Forecast, 2017 – 2025 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
7.1.3. Market Opportunity Analysis
7.2. Heterologus
7.2.1. Market Analysis and Forecast, 2017 – 2025 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
7.2.3. Market Opportunity Analysis
8. GLOBAL ANTIVENOM MARKET FORECAST, BY DISTRIBUTION CHANNEL, 2017 - 2023
8.1. Hospital Pharmacies
8.1.1. Market Analysis and Forecast, 2017 – 2025 (Revenue, USD Mn)
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
8.1.3. Market Opportunity Analysis
8.2. Retail Pharmacies
8.2.1. Market Analysis and Forecast, 2017 – 2025 (Revenue, USD Mn)
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
8.2.3. Market Opportunity Analysis
9. GLOBAL ANTIVENOM MARKET FORECAST, BY REGION, 2017 - 2023
9.1. North America
9.1.1. Market Analysis and Forecast, 2017 – 2025 (Revenue, USD Mn)
9.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
9.1.3. Market Opportunity Analysis
9.2. Europe
9.2.1. Market Analysis and Forecast, 2017 – 2025 (Revenue, USD Mn)
9.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
9.2.3. Market Opportunity Analysis
9.3. Asia-Pacific
9.3.1. Market Analysis and Forecast, 2017 – 2025 (Revenue, USD Mn)
9.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
9.3.3. Market Opportunity Analysis
9.4. Latin America
9.4.1. Market Analysis and Forecast, 2017 – 2025 (Revenue, USD Mn)
9.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
9.4.3. Market Opportunity Analysis
9.5. Middle East & Africa
9.5.1. Market Analysis and Forecast, 2017 – 2025 (Revenue, USD Mn)
9.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
9.5.3. Market Opportunity Analysis
9.6. Global Antivenom Market - Opportunity Analysis Index, By Antivenom Type, Reptile Type, Immunoglobulin Type, Distribution Channel and Region, 2017 – 2025
10. NORTH AMERICA ANTIVENOM MARKET ANALYSIS 2017 - 2023
10.1.1. Antivenom Type Analysis Forecast (2017 – 2025) by Revenue (USD Mn), Y-o-Y
Growth (%), and Market Share (%)
10.1.1.1. Monovalent
10.1.1.2. Bivalent
10.1.1.3. Trivalent
10.1.1.4. Tetravalent
10.1.1.5. Polyvalent
10.1.2. Reptile Type Analysis Forecast (2017 – 2025) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.1.2.1. Snakes
10.1.2.2. Scorpions
10.1.2.3. Others
10.1.3. Immunoglobulin Type Analysis Forecast (2017 – 2025) by Revenue (USD Mn), Y-o-Y
Growth (%), and Market Share (%)
10.1.3.1. Homologous
10.1.3.2. Heterologous
10.1.4.Distribution Channel Analysis Forecast (2017 – 2025) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.1.4.1. Hospital Pharmacies
10.1.4.2. Retail Pharmacies
10.1.4.5. Others
10.1.5. Country Analysis Forecast (2017 – 2025) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.1.5.1. U.S
10.1.5.2. Canada
10.1.6. North America Antivenom Market - Opportunity Analysis Index, By Antivenom Type, Reptile Type, Immunoglobulin Type, Distribution Channel, and Country, 2017 – 2025
10.1.7. North America Antivenom Market Dynamics - Trends
11. EUROPE ANTIVENOM MARKET ANALYSIS 2017 - 2023
11.1.1.Antivenom Type Analysis Forecast (2017 – 2025) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.1.1. Monovalent
11.1.1.2. Bivalent
11.1.1.3. Trivalent
11.1.1.4. Tetravalent
11.1.1.5. Polyvalent
11.1.2.Reptile Type Analysis Forecast (2017 – 2025) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.2 Snakes
11.1.2.1. Scorpions
11.1.2.2. Others
11.1.3.Immunoglobulin Type Analysis Forecast (2017 – 2025) by Revenue (USD Mn), -o-Y Growth (%), and Market Share (%)
11.1.3.1. Homologous
11.1.3.2. Heterologus
11.1.4.Distribution Channel Analysis Forecast (2017 – 2025) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.4.1. Hospital Pharmacies
11.1.4.2. Retail Pharmacies
11.1.4.5. Others
11.1.5. Country Analysis Forecast (2017 – 2025) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.5.1. Germany
11.1.5.2. UK
11.1.5.3. France
11.1.5.4. Italy
11.1.5.5. Spain
11.1.5.6. Poland
11.1.5.7. Russia
11.1.5.8. Rest of Europe
11.1.6. Europe Antivenom Market - Opportunity Analysis Index, By Antivenom Type, Reptile Type, Immunoglobulin Type, Distribution Channel, and Country, 2017 – 2025
11.1.7. Europe Antivenom Market Dynamics - Trends
12. ASIA-PACIFIC ANTIVENOM MARKET ANALYSIS 2017 - 2023
12.1.1.Antivenom Type Analysis Forecast (2017 – 2025) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.1.1. Monovalent
12.1.1.2. Bivalent
12.1.1.3. Trivalent
12.1.1.4. Tetravalent
12.1.1.5. Polyvalent
12.1.2. Reptile Type Analysis Forecast (2017 – 2025) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.2.1. Snakes
12.1.2.2. Scorpions
12.1.2.3. Others
12.1.3. Immunoglobulin Type Analysis Forecast (2017 – 2025) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.3.1. Homologous
12.1.3.2. Heterologous
12.1.4. Distribution Channel Analysis Forecast (2017 – 2025) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.4.1. Hospital Pharmacies
12.1.4.2. Retail Pharmacies
12.1.4.5. Others
12.1.5. Country Analysis Forecast (2017 – 2025) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.5.1. Japan
12.1.5.2. China
12.1.5.3. India
12.1.5.4. ASEAN
12.1.5.5. Australia & New Zealand
12.1.5.6. Rest of APAC
12.1.6. Asia-Pacific Antivenom Market - Opportunity Analysis Index, By Antivenom Type, Reptile Type, Immunoglobulin Type, Distribution Channel, and Country, 2017 – 2025
12.1.7. Asia-Pacific Antivenom Market Dynamics - Trends
13. LATIN AMERICA ANTIVENOM MARKET ANALYSIS 2017 - 2023
13.1.1. Antivenom Type Analysis Forecast (2017 – 2025) by Revenue (USD Mn), Y-o-Y
Growth (%), and Market Share (%)
13.1.1.1. Monovalent
13.1.1.2. Bivalent
13.1.1.3. Trivalent
13.1.1.4. Tetravalent
13.1.1.5. Polyvalent
13.1.2. Reptile Type Analysis Forecast (2017 – 2025) by Revenue (USD Mn), Y-o-Y
Growth (%), and Market Share (%)
13.1.2.1. Snakes
13.1.2.2. Scorpions
13.1.2.3. Others
13.1.3. Immunoglobulin Type Analysis Forecast (2017 – 2025) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.1.3.1. Homologous
13.1.3.2. Heterologous
13.1.4. Distribution Channel Analysis Forecast (2017 – 2025) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.1.4.1. Hospital Pharmacies
13.1.4.2. Retail Pharmacies
13.1.4.5. Others
13.1.5. Country Analysis Forecast (2017 – 2025) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.1.5.1. Brazil
13.1.5.2. Mexico
13.1.5.3. Argentina
13.1.5.4. Venezuela
13.1.5.5. Rest of Latin America
13.1.6. Latin America Antivenom Market - Opportunity Analysis Index, By Antivenom Type, Reptile Type, Immunoglobulin Type, Distribution Channel, and Country, 2017 – 2025
13.1.7. Latin America Antivenom Market Dynamics - Trends
14. MIDDLE EAST & AFRICA ANTIVENOM MARKET ANALYSIS 2017 - 2023
14.1.1.Antivenom Type Analysis Forecast (2017 – 2025) by Revenue (USD Mn), Y-o-Y
Growth (%), and Market Share (%)
14.1.1.1. Monovalent
14.1.1.2. Bivalent
14.1.1.3. Trivalent
14.1.1.4. Tetravalent
14.1.1.5. Polyvalent
14.1.1.6.
14.1.1.7.
14.1.1.9.
14.1.2.Reptile Type Analysis Forecast (2017 – 2025) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
14.1.2.1. Snakes
14.1.2.2. Scorpions
14.1.2.3. Others
14.1.3.Immunoglobulin Type Analysis Forecast (2017 – 2025) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
14.1.3.1. Homologous
14.1.3.2. Heterologous
14.1.4.Distribution Channel Analysis Forecast (2017 – 2025) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
14.1.4.1. Hospital Pharmacies
14.1.4.2. Retail Pharmacies
14.1.4.5. Others
14.1.5. Country Analysis Forecast (2017 – 2025) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
14.1.5.1. Gulf Cooperation Council (GCC) Countries
14.1.5.2. Israel
14.1.5.3. South Africa
14.1.5.4. Rest of MEA
14.1.6. Middle East & Africa Antivenom Market - Opportunity Analysis Index, By Antivenom
Type, Reptile Type, Immunoglobulin Type, Distribution Channel, and Country, 2017 – 2025
14.1.7. Middle East & Africa Dynamics - Trends
15. COMPETITION LANDSCAPE
15.1. Strategic Dashboard of Top Market Players
15.2. Company Profiles (Introduction, Financial Analysis Product & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
15.2.1. Vins Bioproducts Limited (India)
15.2.2. Bharat Serum and Vaccines Limited (India)
15.2.3. CSL Limited (Victoria)
15.2.4. Rare Disease Therapeutics, Inc. (U.S.)
15.2.5. F. Hoffmann-La Roche AG (Switzerland)
15.2.6. Instituto Bioclon, S.A. de C.V.(Mexico)
15.2.7. Incepta Vaccine Ltd. (Bangladesh)
15.2.8. BTG Plc (UK)
15.2.9. Merck & Co., Inc. (U.S)
15.2.10. Pfizer Inc. (U.S.)
16. RESEARCH METHODOLOGY
17. KEY ASSUMPTIONS AND ACRONY
